Dear editor
In a recently published paper 1 fosfomycin is claimed to be an effective antibiotic on
Gram-negative bacteria (GNBs) causing urinary tract infections (UTIs) in Pondicherry in Southern India. Monotherapy of fosfomycin is not recommended due to chances for development of resistance during therapy is a serious concern 2 therefore the authors suggested using fosfomycin with amoxyclav and nitrofurantoin. 1 Researchers reported fosfomycin as the most effective antibiotic inhibiting 100% E. coli, 70% Klebsiella sp., and 50% Pseudomonas sp. and 40% Enterobacter sp. isolates from UTIs. Fosfomycin was also effective against extended-spectrum β-lactamases (ESBL), carbapenemase and AmpC 1 producers.
A recent report from Bareilly 3 , Northern India indicated E. coli as the most common bacteria associated with UTI infections both in humans and animals similar to the report from Pondicherry. 1 However, the report from Northern India reported only that only 12.9% and 33.3% isolates of GNBs associated with UTIs in humans and animals were susceptible to fosfomycin. The study 3 reported that only 8.3% and 25% of E. coli isolates from UTI cases were susceptible to fosfomycin. The two studies 1,3 concurred (Table 1 ) each other concerning the efficacy of meropenem and nitrofurantoin but contradicted each other for the susceptibility of E. coli isolates (Table 1 ) and other GNBs from UTIs to other antibiotics. http://doi.org/10.2147/IDR.S224769 variation in susceptibility (Table 1) of the bacteria from different regions and different patients causing similar infections. Thus, a generalization of observation should be avoided for suggesting or using antimicrobial chemotherapy, and more elaborate and continues surveys and monitoring the antimicrobial drug-resistance of important pathogens should be established and regularly published for proper guidance of the clinicians.
